Citigroup
UNCY icon

Citigroup’s Unicycive Therapeutics UNCY Stock Holding History

Citigroup’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7 Sell
1
-227
-100% -$1.49K ﹤0.01% 5761
2025
Q4 		$1.32K Sell
228
-6,464
-97% -$34.5K ﹤0.01% 5515
2025
Q3 		$29.2K Buy
+6,692
New +$29.2K ﹤0.01% 4674
2025
Q1 		– Sell
-59
Closed -$466 – 5979
2024
Q4 		$466 Buy
+59
New +$327 ﹤0.01% 5629

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's UNCY Position: Q1 2026 in Review

Citigroup reduced its Unicycive Therapeutics (UNCY) stake by 100% in Q1 2026, selling an estimated $1.49K and leaving 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #5761.

Citigroup first reported a position in UNCY in Q4 2024 and has held it in 4 quarters since. The position peaked at $29.2K in Q3 2025. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Citigroup held 1 share of Unicycive Therapeutics worth $7 as of Q1 2026.
  • Citigroup sold 227 Unicycive Therapeutics shares in Q1 2026, an estimated $1.49K.
  • Unicycive Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5761 holding.
  • Citigroup first reported a position in Unicycive Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Citigroup's Unicycive Therapeutics position peaked at $29.2K in Q3 2025.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.